Ligand id: 7299

Name: tadalafil

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: tadalafil

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 1
Topological polar surface area 74.87
Molecular weight 389.14
XLogP 1.75
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used to treat erectile dysfunction (ED), benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension. The drug used to treat ED and BPH is approved as Cialis, and the drug approved for pulmonary arterial hypertension is Adcirca. Approvals for different indications have separate approval dates.
Mechanism Of Action and Pharmacodynamic Effects
Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor. Such inhibitors block the degradative action of PDE5 on cGMP in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis. This action dilates these blood vessels allowing blood ingress and leads to functional erection. Vasoconstriction in the pulmonary vascular lumen causes PAH and tadalafil can also effect vasodilation in these vessels, thus reducing pulmonary arterial pressure. Due to its extended elimination half-life compared to other PDE5 inhibitors [1], this drug is useful for once-a-day dosing for patients with pulmonary arterial hypertension.
External links